α-Ketoisocaproate is superior to leucine in sparing glucose utilization in humans

R. Buckspan, B. Hoxworth, Eugenio Cersosimo, J. Devlin, E. Horton, N. Abumrad

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The present study was designed to examine the glucose-sparing effect of leucine and its keto acid α-ketoisocaproate (KIC) in vivo. Two groups of overnight-fasted normal volunteers were studied. In the first group, eight subjects received an intravenous infusion of leucine and six subjects received KIC (2.3 μmol·kg-1·min-1) for 3 h; on another occasion, all subjects received saline and acted as their own controls. In the second group, 11 subjects received an infusion of 1 mU·kg-1·min-1 for 3 h with a variable glucose infusion to maintain euglycemia. On another occasion, five subjects received an additional infusion of leucine and six subjects received KIC each at 2.3 μmol·kg-1·min-1 for 3 h. The amount of exogenous glucose required to maintain euglucemia (M, mg·kg-1·min-1) was used as an index of total body glucose utilization. Forearm exchange of leucine, KIC, glucose, and lactate was determined in both groups. Both leucine and KIC infusions alone decreased glucose uptake (42 and 40%) and increased lactate release (37 and 116%, respectively). Hyperinsulinemia (6-fold basal) and euglycemia resulted in a fivefold increase in glucose uptake across the human forearm. The amount of exogenous glucose required to maintain euglycemia averaged 7.4 ± 0.5 mg·kg-1·min-1. The combination of leucine and insulin infusions did not alter the stimulated forearm glucose uptake nor did it change M (7.25 ± 0.6 mg·kg-1·min-1, P = NS). On the other hand, the combination of KIC and insulin resulted in a near 20% decrease in both forearm glucose uptake and an increase in the amount of lactate release across the forearm (P < 0.05, both). Our data indicate that KIC is more potent than its parent amino acid, leucine, in sparing glucose utilization in humans. The exact mechanism of this effect is not clear but is most likely related to both an inhibition of glycogen deposition by skeletal muscle and inhibition of pyruvate dehydrogenase enzyme complex by the same tissues.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume251
Issue number6
StatePublished - 1986
Externally publishedYes

Fingerprint

Leucine
Glucose
Forearm
Lactic Acid
Insulin
Pyruvate Dehydrogenase Complex
Keto Acids
Hyperinsulinism
Pyruvic Acid
Glycogen
Intravenous Infusions
Muscle
Healthy Volunteers
Oxidoreductases
Skeletal Muscle
Tissue
Amino Acids

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Biochemistry

Cite this

α-Ketoisocaproate is superior to leucine in sparing glucose utilization in humans. / Buckspan, R.; Hoxworth, B.; Cersosimo, Eugenio; Devlin, J.; Horton, E.; Abumrad, N.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 251, No. 6, 1986.

Research output: Contribution to journalArticle

@article{976f66c38eee40d1af667d9058f9cd16,
title = "α-Ketoisocaproate is superior to leucine in sparing glucose utilization in humans",
abstract = "The present study was designed to examine the glucose-sparing effect of leucine and its keto acid α-ketoisocaproate (KIC) in vivo. Two groups of overnight-fasted normal volunteers were studied. In the first group, eight subjects received an intravenous infusion of leucine and six subjects received KIC (2.3 μmol·kg-1·min-1) for 3 h; on another occasion, all subjects received saline and acted as their own controls. In the second group, 11 subjects received an infusion of 1 mU·kg-1·min-1 for 3 h with a variable glucose infusion to maintain euglycemia. On another occasion, five subjects received an additional infusion of leucine and six subjects received KIC each at 2.3 μmol·kg-1·min-1 for 3 h. The amount of exogenous glucose required to maintain euglucemia (M, mg·kg-1·min-1) was used as an index of total body glucose utilization. Forearm exchange of leucine, KIC, glucose, and lactate was determined in both groups. Both leucine and KIC infusions alone decreased glucose uptake (42 and 40{\%}) and increased lactate release (37 and 116{\%}, respectively). Hyperinsulinemia (6-fold basal) and euglycemia resulted in a fivefold increase in glucose uptake across the human forearm. The amount of exogenous glucose required to maintain euglycemia averaged 7.4 ± 0.5 mg·kg-1·min-1. The combination of leucine and insulin infusions did not alter the stimulated forearm glucose uptake nor did it change M (7.25 ± 0.6 mg·kg-1·min-1, P = NS). On the other hand, the combination of KIC and insulin resulted in a near 20{\%} decrease in both forearm glucose uptake and an increase in the amount of lactate release across the forearm (P < 0.05, both). Our data indicate that KIC is more potent than its parent amino acid, leucine, in sparing glucose utilization in humans. The exact mechanism of this effect is not clear but is most likely related to both an inhibition of glycogen deposition by skeletal muscle and inhibition of pyruvate dehydrogenase enzyme complex by the same tissues.",
author = "R. Buckspan and B. Hoxworth and Eugenio Cersosimo and J. Devlin and E. Horton and N. Abumrad",
year = "1986",
language = "English (US)",
volume = "251",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - α-Ketoisocaproate is superior to leucine in sparing glucose utilization in humans

AU - Buckspan, R.

AU - Hoxworth, B.

AU - Cersosimo, Eugenio

AU - Devlin, J.

AU - Horton, E.

AU - Abumrad, N.

PY - 1986

Y1 - 1986

N2 - The present study was designed to examine the glucose-sparing effect of leucine and its keto acid α-ketoisocaproate (KIC) in vivo. Two groups of overnight-fasted normal volunteers were studied. In the first group, eight subjects received an intravenous infusion of leucine and six subjects received KIC (2.3 μmol·kg-1·min-1) for 3 h; on another occasion, all subjects received saline and acted as their own controls. In the second group, 11 subjects received an infusion of 1 mU·kg-1·min-1 for 3 h with a variable glucose infusion to maintain euglycemia. On another occasion, five subjects received an additional infusion of leucine and six subjects received KIC each at 2.3 μmol·kg-1·min-1 for 3 h. The amount of exogenous glucose required to maintain euglucemia (M, mg·kg-1·min-1) was used as an index of total body glucose utilization. Forearm exchange of leucine, KIC, glucose, and lactate was determined in both groups. Both leucine and KIC infusions alone decreased glucose uptake (42 and 40%) and increased lactate release (37 and 116%, respectively). Hyperinsulinemia (6-fold basal) and euglycemia resulted in a fivefold increase in glucose uptake across the human forearm. The amount of exogenous glucose required to maintain euglycemia averaged 7.4 ± 0.5 mg·kg-1·min-1. The combination of leucine and insulin infusions did not alter the stimulated forearm glucose uptake nor did it change M (7.25 ± 0.6 mg·kg-1·min-1, P = NS). On the other hand, the combination of KIC and insulin resulted in a near 20% decrease in both forearm glucose uptake and an increase in the amount of lactate release across the forearm (P < 0.05, both). Our data indicate that KIC is more potent than its parent amino acid, leucine, in sparing glucose utilization in humans. The exact mechanism of this effect is not clear but is most likely related to both an inhibition of glycogen deposition by skeletal muscle and inhibition of pyruvate dehydrogenase enzyme complex by the same tissues.

AB - The present study was designed to examine the glucose-sparing effect of leucine and its keto acid α-ketoisocaproate (KIC) in vivo. Two groups of overnight-fasted normal volunteers were studied. In the first group, eight subjects received an intravenous infusion of leucine and six subjects received KIC (2.3 μmol·kg-1·min-1) for 3 h; on another occasion, all subjects received saline and acted as their own controls. In the second group, 11 subjects received an infusion of 1 mU·kg-1·min-1 for 3 h with a variable glucose infusion to maintain euglycemia. On another occasion, five subjects received an additional infusion of leucine and six subjects received KIC each at 2.3 μmol·kg-1·min-1 for 3 h. The amount of exogenous glucose required to maintain euglucemia (M, mg·kg-1·min-1) was used as an index of total body glucose utilization. Forearm exchange of leucine, KIC, glucose, and lactate was determined in both groups. Both leucine and KIC infusions alone decreased glucose uptake (42 and 40%) and increased lactate release (37 and 116%, respectively). Hyperinsulinemia (6-fold basal) and euglycemia resulted in a fivefold increase in glucose uptake across the human forearm. The amount of exogenous glucose required to maintain euglycemia averaged 7.4 ± 0.5 mg·kg-1·min-1. The combination of leucine and insulin infusions did not alter the stimulated forearm glucose uptake nor did it change M (7.25 ± 0.6 mg·kg-1·min-1, P = NS). On the other hand, the combination of KIC and insulin resulted in a near 20% decrease in both forearm glucose uptake and an increase in the amount of lactate release across the forearm (P < 0.05, both). Our data indicate that KIC is more potent than its parent amino acid, leucine, in sparing glucose utilization in humans. The exact mechanism of this effect is not clear but is most likely related to both an inhibition of glycogen deposition by skeletal muscle and inhibition of pyruvate dehydrogenase enzyme complex by the same tissues.

UR - http://www.scopus.com/inward/record.url?scp=0023005985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023005985&partnerID=8YFLogxK

M3 - Article

C2 - 3538898

AN - SCOPUS:0023005985

VL - 251

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 6

ER -